WW International Shares Jump On BCBS Michigan’s Revised Authorization For Wegovy, Other Weight Loss Drugs
Shares of WW International Inc (NASDAQ:WW) spiked as much as 15% on Friday after Blue Cross Blue Shield…
On September 19, Reshape Lifesciences Entered Into Exclusive License Agreement With Biorad Medysis Pvt. Ltd.;
- SEC Filing On September 19, 2023, ReShape Lifesciences Inc. (the "Company") entered into an Exclusive License Agreement (the "License Agreement") with Biorad Medysis Pvt. Ltd. ("Biorad"), pursuant to which
Optimism Surrounds Cancer Focused Ikena Oncology, Analyst Initiates With Outperform
Ikena Oncology Inc (NASDAQ: IKNA) is garnering attention with its oncology-focused pipeline, and the company's recent developments have raised optimism in the medical community.
Why Is Seagen Stock Trading Higher Today?
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC:
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC:
Bristol Myers’ Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study
Bristol Myers Squibb & Co (NYSE: BMY) announced interim data from Phase 3 CheckMate -77T trial evaluating the perioperative regimen of neoadjuvant (before surgery) Opdivo (nivolumab) with chemotherapy followed by surgery and
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze For The Treatment Of Acute Lymphoblastic Leukemia And Lymphoblastic Lymphoma
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner Jazz Pharmaceuticals plc (NASDAQ:JAZZ), ("Jazz") has been granted marketing authorization by the European Commission (EC) for Enrylaze®
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These human studies, crucial to drug development, can take years and accrue costs in the billions.
Better Than Chemotherapy – AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:
Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.)